Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

Fig. 3

Results of the comparison study. a PFS in patients treated with G/E or afatinib in a first-line EGFR-TKI setting. b Frequency of EGFR driver (left), T790M mutation in all patients (middle) and T790M mutation in EGFR driver mutation positive patients in plasma (right) according to the types of EGFR-TKIs (afatinib vs. gefitinib and/or erlotinib). c PFS of osimertinib after afatinib and G/E failure

Back to article page